• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

Introduction to 2-(difluoromethyl)prop-2-enoic acid (CAS No. 383-94-8)

2-(difluoromethyl)prop-2-enoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 383-94-8, is a fluorinated carboxylic acid derivative that has garnered significant attention in the field of pharmaceutical and agrochemical research. This compound, characterized by its bifluoromethyl substituent on the prop-2-enyl backbone, exhibits unique chemical and biological properties that make it a valuable intermediate in synthetic chemistry and a potential candidate for drug development.

The structural motif of 2-(difluoromethyl)prop-2-enoic acid consists of a conjugated system featuring a double bond adjacent to both a carboxylic acid group and a difluoromethyl side chain. This arrangement imparts distinct reactivity patterns, enabling its utility in various synthetic transformations. The presence of the difluoromethyl group, in particular, is noteworthy due to its ability to modulate metabolic stability, lipophilicity, and binding affinity in biological targets.

In recent years, the pharmaceutical industry has shown increasing interest in fluorinated compounds due to their enhanced pharmacokinetic profiles. 2-(difluoromethyl)prop-2-enoic acid serves as a versatile building block for constructing more complex molecules with improved therapeutic efficacy. Its incorporation into drug candidates has been explored in the development of inhibitors targeting enzymes involved in cancer metabolism and inflammation.

One of the most compelling aspects of 2-(difluoromethyl)prop-2-enoic acid is its role in medicinal chemistry as a key intermediate for synthesizing small-molecule inhibitors. For instance, researchers have leveraged this compound to develop novel agents that disrupt metabolic pathways dysregulated in diseases such as cancer. The bifluoromethyl group's electronic properties contribute to selective binding interactions with biological targets, enhancing drug potency while minimizing off-target effects.

Recent studies have highlighted the utility of 2-(difluoromethyl)prop-2-enoic acid in designing protease inhibitors, particularly those targeting matrix metalloproteinases (MMPs), which are implicated in tumor invasion and angiogenesis. The fluorine atoms' ability to increase metabolic stability has been exploited to prolong the half-life of these inhibitors, improving their clinical applicability. Additionally, modifications of the prop-2-enyl backbone have allowed for fine-tuning of physicochemical properties, leading to more optimized drug candidates.

The agrochemical sector has also benefited from the incorporation of 2-(difluoromethyl)prop-2-enoic acid into next-generation pesticides. Its structural features contribute to enhanced bioavailability and resistance against degradation, ensuring prolonged activity in controlling pests and pathogens. This has been particularly relevant in addressing challenges associated with agricultural resistance and environmental sustainability.

Synthetic methodologies for preparing 2-(difluoromethyl)prop-2-enoic acid have seen considerable advancements, enabling scalable production under controlled conditions. Modern synthetic routes often involve fluorination strategies that introduce the difluoromethyl group with high selectivity and yield. These developments have facilitated access to this compound for both academic research and industrial applications.

The biological activity of derivatives of 2-(difluoromethyl)prop-2-enoic acid continues to be a subject of active investigation. Preclinical studies have demonstrated promising results in models of inflammation and autoimmunity, where compounds incorporating this scaffold exhibit potent modulatory effects on key signaling pathways. Such findings underscore the potential of further exploring this class of molecules for therapeutic intervention.

As research progresses, the demand for high-quality intermediates like 2-(difluoromethyl)prop-2-enoic acid is expected to grow, driven by the need for innovative solutions in drug discovery and agricultural science. The compound's unique structural features and functional versatility position it as a cornerstone in synthetic chemistry applications across multiple domains.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)